Mergers & AcquisitionsBy The Online Investor Staff, updated Wed., Feb. 26, 6:28 PM
|This Slide: #35 of 100|
Slide #35. Meridian Bioscience, Inc. — Exalenz Bioscience Ltd.
Meridian Bioscience, Inc. (NASDAQ:VIVO)
Exalenz Bioscience Ltd.
Meridian Bioscience, Inc. (NASDAQ: VIVO) and Exalenz Bioscience Ltd. (TASE: EXEN) announced today that the two companies have entered into a definitive agreement for Meridian to acquire Exalenz for 6.10 per share in cash with an implied transaction value of approximately $49 million. The agreement has been approved unanimously by the boards of directors of both companies.
Meridian Bioscience is a life science company with principal businesses in the development, manufacture, sale and distribution of diagnostic test kits, primarily for certain gastrointestinal and respiratory infectious diseases, and elevated blood lead levels, and the manufacture and distribution of bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, and bioresearch reagents used by IVD manufacturers and researchers in immunological and molecular tests for human, animal, plant and environmental applications. Co.'s reportable segments are: Diagnostics, which products span a menu of testing platforms and technologies; and Life Science.
VIVO SEC Filing Email Alerts Service
Open the VIVO Page at The Online Investor »
Sell (1.33 out of 4)
(ranked lower than approx. 100% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite